Novel anti-inflammatory activity of sunitinib malate identified in a macrophage drug-repurposing screen of FDA-approved medicines

Novel anti-inflammatory activity of sunitinib malate identified in a macrophage drug-repurposing screen of FDA-approved medicines

Bibliographic Details
Main Authors:	Chaffey, L, Bowman, A, O'Brien, C, Roberti, A, Purvis, G, Greaves, D
Format:	Conference item
Language:	English
Published:	Wiley 2021

Similar Items

NF-κB Signaling and Inflammation—Drug Repurposing to Treat Inflammatory Disorders?
by: Annabell Roberti, et al.
Published: (2022-02-01)

Anti-inflammatory activity of repurposed tyrosine kinase inhibitors in macrophages
by: Chaffey, L
Published: (2023)

Drug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities
by: Laura Chaffey, et al.
Published: (2022-10-01)

Impact of Nutrition or FDA-Approved Medicine Repurposing on Metabolic Syndrome and Diabetic Complications
by: Lu Cai
Published: (2023-05-01)

Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
by: Matthew Cannon, et al.
Published: (2020-07-01)

Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
by: Sergey Shityakov, et al.
Published: (2021-10-01)

Development and validation of a HPTLC method for analysis of Sunitinib malate
by: Monireh Hajmalek, et al.

Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML
by: Jenna R. James, et al.
Published: (2023-02-01)

Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report
by: Sakashita Hiroyuki, et al.
Published: (2010-11-01)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
by: Devika Sirohi, et al.
Published: (2017-07-01)

Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection
by: Ashwini eBenedict, et al.
Published: (2015-07-01)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
by: Jyothi Dhuguru, et al.
Published: (2022-01-01)

Repurposing of Food and Drug Admnistration (FDA) approved library to identify a potential inhibitor of trypanothione synthetase for developing an antileishmanial agent
by: Divya Vemula, et al.
Published: (2024-03-01)

Sunitinib malate induces cell death in adult human cardiac progenitor cells
by: Robert Walmsley, et al.
Published: (2024-01-01)

Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate
by: Joan Manel Gasent Blesa, et al.
Published: (2009-12-01)

Computational and Experimental Drug Repurposing of FDA-Approved Compounds Targeting the Cannabinoid Receptor CB1
by: Emanuele Criscuolo, et al.
Published: (2023-12-01)

Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs
by: Valentina L. Kouznetsova, et al.
Published: (2020-09-01)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
by: Dr. Chenshu Xu, et al.
Published: (2021-09-01)

Repurposing of FDA approved antibiotics as antimalarial agents: A network pharmacology based in silico approach
by: B. Gogoi, et al.
Published: (2020-12-01)

Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats
by: Zulfiqar Z, et al.
Published: (2020-12-01)

Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis.
by: Bin Li, et al.
Published: (2014-01-01)

Repurposing of US-FDA-approved drugs as negative modulators of ubiquitin specific protease-7 (USP7)
by: Seema Zadi, et al.
Published: (2024-03-01)

Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches
by: Omima S. Mohammed, et al.
Published: (2023-11-01)

In Silico and In Vitro Potential of FDA-Approved Drugs for Antimalarial Drug Repurposing against Plasmodium Serine Hydroxymethyltransferases
by: Pitchayathida Mee-udorn, et al.
Published: (2023-09-01)

Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats [Retraction]
by: Zulfiqar Z, et al.
Published: (2022-11-01)

Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study
by: Alfred Olaoluwa Akinlalu, et al.
Published: (2021-09-01)

Targeting NF-κB signaling in macrophages through drug repurposing
by: Roberti, A
Published: (2024)

Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes
by: Lorenzo Flori, et al.
Published: (2023-04-01)

Repurposing of FDA-Approved NSAIDs for DPP-4 Inhibition as an Alternative for Diabetes Mellitus Treatment: Computational and in Vitro Study
by: Veera C. S. R. Chittepu, et al.
Published: (2019-05-01)

Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease.
by: Marcus M Ilg, et al.
Published: (2022-01-01)

FDA-Approved Amoxapine Effectively Promotes Macrophage Control of Mycobacteria by Inducing Autophagy
by: Jia Wang, et al.
Published: (2022-10-01)

A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection
by: Abo-zeid, Yasmin, et al.
Published: (2020)

Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma
by: Magdalena Rausch, et al.
Published: (2021-08-01)

Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma
by: Jacob W. Greenberg, et al.
Published: (2021-05-01)

Boosting the Anticancer Activity of Sunitinib Malate in Breast Cancer through Lipid Polymer Hybrid Nanoparticles Approach
by: Mohammed Muqtader Ahmed, et al.
Published: (2022-06-01)

Magnetic solid phase extraction of Sunitinib malate in urine samples assisted with mixed hemimicelle and spectrophotometric detection
by: Eslam Pourbasheer, et al.
Published: (2023-02-01)

FDA Approvals of Biologics in 2022
by: Alexander C. Martins, et al.
Published: (2023-05-01)

Sensory Ion Channel Candidates Inform on the Clinical Course of Pancreatic Cancer and Present Potential Targets for Repurposing of FDA-Approved Agents
by: Wenjie Shi, et al.
Published: (2022-03-01)

In Silico Drug Repurposing Approach: Investigation of <i>Mycobacterium tuberculosis</i> FadD32 Targeted by FDA-Approved Drugs
by: Nolwazi Thobeka Portia Ngidi, et al.
Published: (2022-01-01)

A Transcriptomics-Based Bioinformatics Approach for Identification and In Vitro Screening of FDA-Approved Drugs for Repurposing against Dengue Virus-2
by: Madhura Punekar, et al.
Published: (2022-09-01)